Advertisement
Changhong Li

Changhong Li

Changhong Li is the chief scientific officer at Hua Medicine. He has a deep well of experience in drug development with a focus on diabetes. He completed a postdoctoral fellowship at the Children’s Hospital of Philadelphia of the University of Pennsylvania and spent 15 years at the same institution as a scientist and research assistant professor. In 2018, he founded Nanjing AscendRate Pharmaceutical Technology Co., which became a subsidiary of Hua Medicine in 2022.
Changhong Li is the chief scientific officer at Hua Medicine. He has a deep well of experience in drug development with a focus on diabetes. He completed a postdoctoral fellowship at the Children’s Hospital of Philadelphia of the University of Pennsylvania and spent 15 years at the same institution as a scientist and research assistant professor. In 2018, he founded Nanjing AscendRate Pharmaceutical Technology Co., which became a subsidiary of Hua Medicine in 2022.
Languages Spoken:
English

Opinion | Why a new approach to diabetes treatment is desperately needed

Current widely used treatment approaches are not fit for task as they ignore the idiosyncrasies in diabetes that can arise in each patient.

videocam
Related Topic
Science